© 2003 by Oxford University Press
© 2003 Oxford University Press
REVIEW |
Hemostatic Regulators of Tumor Angiogenesis: A Source of Antiangiogenic Agents for Cancer Treatment?
Affiliations of authors: Academic Unit of Hematology (MED), Academic Unit of Surgical Oncology (MR), and Academic Unit of Pathology (CEL), School of Medicine and Biomedical Sciences, Sheffield, United Kingdom; Academic Oncology Unit, Mount Vernon Hospital, Northwood, Middlesex, United Kingdom (AM).
Correspondence to: Claire E. Lewis, PhD, Academic Unit of Pathology, School of Medicine & Biomedical Sciences, Beech Hill Rd., Sheffield S10 2RX, United Kingdom (e-mail: Claire.lewis{at}sheffield.ac.uk)
The maintenance of vascular integrity and control of blood loss are regulated by a sophisticated system of circulating and cell-associated hemostatic factors. These factors control local platelet aggregation, the conversion of soluble fibrinogen to an insoluble fibrin polymer, and the dissolution of fibrin. However, hemostatic factors are also involved in a number of physiologic processes, including development, tissue remodeling, wound repair, reproduction, inflammation, and angiogenesis. In this review, we outline ways in which angiogenesis is coordinated with and regulated by hemostasis. We focus on inhibitors of angiogenesis contained within platelets or harbored as cryptic fragments of hemostatic proteins and assess the experimental and preclinical evidence for their ability to inhibit tumor angiogenesis and, thus, their potential to be anticancer agents. Finally, we review the results of recent clinical trials involving angiogenesis inhibitors and the evidence that antiangiogenic therapy may be associated with hemostatic complications.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. E. Holmes, J. C. Huang, T. R. Pace, A. B. Howard, and H. B. Muss Tamoxifen and Aromatase Inhibitors Differentially Affect Vascular Endothelial Growth Factor and Endostatin Levels in Women with Breast Cancer Clin. Cancer Res., May 15, 2008; 14(10): 3070 - 3076. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. W.M. van Hinsbergh and P. Koolwijk Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead Cardiovasc Res, May 1, 2008; 78(2): 203 - 212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Italiano Jr, J. L. Richardson, S. Patel-Hett, E. Battinelli, A. Zaslavsky, S. Short, S. Ryeom, J. Folkman, and G. L. Klement Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet {alpha} granules and differentially released Blood, February 1, 2008; 111(3): 1227 - 1233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Persigehl, R. Bieker, L. Matuszewski, A. Wall, T. Kessler, H. Kooijman, N. Meier, W. Ebert, W. E. Berdel, W. Heindel, et al. Antiangiogenic Tumor Treatment: Early Noninvasive Monitoring with USPIO-enhanced MR Imaging in Mice Radiology, August 1, 2007; 244(2): 449 - 456. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M.W. Verheul, H. Hammers, K. van Erp, Y. Wei, T. Sanni, B. Salumbides, D. Z. Qian, G. D. Yancopoulos, and R. Pili Vascular Endothelial Growth Factor Trap Blocks Tumor Growth, Metastasis Formation, and Vascular Leakage in an Orthotopic Murine Renal Cell Cancer Model Clin. Cancer Res., July 15, 2007; 13(14): 4201 - 4208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. A HATOUM, J. HEIDEMANN, and D. G BINION The intestinal microvasculature as a therapeutic target in inflammatory bowel disease. Ann. N.Y. Acad. Sci., August 1, 2006; 1072: 78 - 97. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. W.M. van Hinsbergh, M. A. Engelse, and P. H.A. Quax Pericellular Proteases in Angiogenesis and Vasculogenesis Arterioscler. Thromb. Vasc. Biol., April 1, 2006; 26(4): 716 - 728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Pisano, C. Aulicino, L. Vesci, B. Casu, A. Naggi, G. Torri, D. Ribatti, M. Belleri, M. Rusnati, and M. Presta Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist Glycobiology, February 1, 2005; 15(2): 1C - 6C. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Presta, P. Oreste, G. Zoppetti, M. Belleri, E. Tanghetti, D. Leali, C. Urbinati, A. Bugatti, R. Ronca, S. Nicoli, et al. Antiangiogenic Activity of Semisynthetic Biotechnological Heparins: Low-Molecular-Weight-Sulfated Escherichia coli K5 Polysaccharide Derivatives as Fibroblast Growth Factor Antagonists Arterioscler. Thromb. Vasc. Biol., January 1, 2005; 25(1): 71 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. de Bruin, G. J. Peters, R. Oerlemans, Y. G. Assaraf, A. J. Masterson, A. D. Adema, B. A. C. Dijkmans, H. M. Pinedo, and G. Jansen Sulfasalazine Down-Regulates the Expression of the Angiogenic Factors Platelet-Derived Endothelial Cell Growth Factor/Thymidine Phosphorylase and Interleukin-8 in Human Monocytic-Macrophage THP1 and U937 Cells Mol. Pharmacol., October 1, 2004; 66(4): 1054 - 1060. [Abstract] [Full Text] [PDF]
|
|